Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

M. S. Dai, P. F. Wu, R. Y. Shyu, J. J. Lu, Tsu Yi Chao

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: Recent data suggest that hepatitis B virus (HBV) reactivation develops in 41% of breast cancer (BC) patients carrying HBV after chemotherapy. Our study aimed to determine the role of preemptive use of lamivudine in BC patients undergoing chemotherapy. Patients and methods: The test group consisted of 11 female patients with BC who were seropositive for hepatitis B surface antigen (HBsAg). Of these, 10 patients were treated in an adjuvant setting and one for metastatic disease. Lamivudine was given from the start of chemotherapy and was maintained until 1 month after the last infusion of chemotherapy. The control group consisted of nine historical BC patients carrying HBV and received similar systemic chemotherapy without preemptive lamivudine. Variables including HBsAg, HBV envelope antigen, anti-HBV envelope antibody, serial serum alanine transaminase (ALT), quantitative HBV viral DNA analysis, and HBV-DNA precore promoter and precore sequence were monitored. Test for emergence of mutant strains, notably nucleotide 550, was performed 6 months after the completion of chemotherapy. Results: All patients tolerated lamivudine well without development of evident HBV reactivation or overt hepatitis. Serum ALT remained unchanged without rebound hepatitis after cessation of chemotherapy and withdrawal of lamivudine. No emergence of lamivudine-selective resistant strain (so-called tyrosine-methionine-aspartate-aspartate mutations) was observed. Conclusions: Our results encourage preemptive use of lamivudine for prevention of HBV reactivation in patients who need short-term chemotherapy.

Original languageEnglish
Pages (from-to)540-546
Number of pages7
JournalLiver International
Volume24
Issue number6
DOIs
Publication statusPublished - Dec 2004
Externally publishedYes

Fingerprint

Lamivudine
Hepatitis B virus
Breast Neoplasms
Drug Therapy
Hepatitis B Surface Antigens
Alanine Transaminase
Aspartic Acid
Hepatitis
Hepatitis B Antibodies
Viral DNA
Serum
Methionine
Tyrosine
Nucleotides
Antigens
Control Groups
Mutation
DNA

Keywords

  • Breast cancer
  • Hepatitis B virus reactivation
  • Lamivudine
  • Preemptive treatment

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. / Dai, M. S.; Wu, P. F.; Shyu, R. Y.; Lu, J. J.; Chao, Tsu Yi.

In: Liver International, Vol. 24, No. 6, 12.2004, p. 540-546.

Research output: Contribution to journalArticle

@article{85142ecf9a8744268d901d36166b63a4,
title = "Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration",
abstract = "Background: Recent data suggest that hepatitis B virus (HBV) reactivation develops in 41{\%} of breast cancer (BC) patients carrying HBV after chemotherapy. Our study aimed to determine the role of preemptive use of lamivudine in BC patients undergoing chemotherapy. Patients and methods: The test group consisted of 11 female patients with BC who were seropositive for hepatitis B surface antigen (HBsAg). Of these, 10 patients were treated in an adjuvant setting and one for metastatic disease. Lamivudine was given from the start of chemotherapy and was maintained until 1 month after the last infusion of chemotherapy. The control group consisted of nine historical BC patients carrying HBV and received similar systemic chemotherapy without preemptive lamivudine. Variables including HBsAg, HBV envelope antigen, anti-HBV envelope antibody, serial serum alanine transaminase (ALT), quantitative HBV viral DNA analysis, and HBV-DNA precore promoter and precore sequence were monitored. Test for emergence of mutant strains, notably nucleotide 550, was performed 6 months after the completion of chemotherapy. Results: All patients tolerated lamivudine well without development of evident HBV reactivation or overt hepatitis. Serum ALT remained unchanged without rebound hepatitis after cessation of chemotherapy and withdrawal of lamivudine. No emergence of lamivudine-selective resistant strain (so-called tyrosine-methionine-aspartate-aspartate mutations) was observed. Conclusions: Our results encourage preemptive use of lamivudine for prevention of HBV reactivation in patients who need short-term chemotherapy.",
keywords = "Breast cancer, Hepatitis B virus reactivation, Lamivudine, Preemptive treatment",
author = "Dai, {M. S.} and Wu, {P. F.} and Shyu, {R. Y.} and Lu, {J. J.} and Chao, {Tsu Yi}",
year = "2004",
month = "12",
doi = "10.1111/j.1478-3231.2004.0964.x",
language = "English",
volume = "24",
pages = "540--546",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

AU - Dai, M. S.

AU - Wu, P. F.

AU - Shyu, R. Y.

AU - Lu, J. J.

AU - Chao, Tsu Yi

PY - 2004/12

Y1 - 2004/12

N2 - Background: Recent data suggest that hepatitis B virus (HBV) reactivation develops in 41% of breast cancer (BC) patients carrying HBV after chemotherapy. Our study aimed to determine the role of preemptive use of lamivudine in BC patients undergoing chemotherapy. Patients and methods: The test group consisted of 11 female patients with BC who were seropositive for hepatitis B surface antigen (HBsAg). Of these, 10 patients were treated in an adjuvant setting and one for metastatic disease. Lamivudine was given from the start of chemotherapy and was maintained until 1 month after the last infusion of chemotherapy. The control group consisted of nine historical BC patients carrying HBV and received similar systemic chemotherapy without preemptive lamivudine. Variables including HBsAg, HBV envelope antigen, anti-HBV envelope antibody, serial serum alanine transaminase (ALT), quantitative HBV viral DNA analysis, and HBV-DNA precore promoter and precore sequence were monitored. Test for emergence of mutant strains, notably nucleotide 550, was performed 6 months after the completion of chemotherapy. Results: All patients tolerated lamivudine well without development of evident HBV reactivation or overt hepatitis. Serum ALT remained unchanged without rebound hepatitis after cessation of chemotherapy and withdrawal of lamivudine. No emergence of lamivudine-selective resistant strain (so-called tyrosine-methionine-aspartate-aspartate mutations) was observed. Conclusions: Our results encourage preemptive use of lamivudine for prevention of HBV reactivation in patients who need short-term chemotherapy.

AB - Background: Recent data suggest that hepatitis B virus (HBV) reactivation develops in 41% of breast cancer (BC) patients carrying HBV after chemotherapy. Our study aimed to determine the role of preemptive use of lamivudine in BC patients undergoing chemotherapy. Patients and methods: The test group consisted of 11 female patients with BC who were seropositive for hepatitis B surface antigen (HBsAg). Of these, 10 patients were treated in an adjuvant setting and one for metastatic disease. Lamivudine was given from the start of chemotherapy and was maintained until 1 month after the last infusion of chemotherapy. The control group consisted of nine historical BC patients carrying HBV and received similar systemic chemotherapy without preemptive lamivudine. Variables including HBsAg, HBV envelope antigen, anti-HBV envelope antibody, serial serum alanine transaminase (ALT), quantitative HBV viral DNA analysis, and HBV-DNA precore promoter and precore sequence were monitored. Test for emergence of mutant strains, notably nucleotide 550, was performed 6 months after the completion of chemotherapy. Results: All patients tolerated lamivudine well without development of evident HBV reactivation or overt hepatitis. Serum ALT remained unchanged without rebound hepatitis after cessation of chemotherapy and withdrawal of lamivudine. No emergence of lamivudine-selective resistant strain (so-called tyrosine-methionine-aspartate-aspartate mutations) was observed. Conclusions: Our results encourage preemptive use of lamivudine for prevention of HBV reactivation in patients who need short-term chemotherapy.

KW - Breast cancer

KW - Hepatitis B virus reactivation

KW - Lamivudine

KW - Preemptive treatment

UR - http://www.scopus.com/inward/record.url?scp=11144287756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144287756&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2004.0964.x

DO - 10.1111/j.1478-3231.2004.0964.x

M3 - Article

C2 - 15566502

AN - SCOPUS:11144287756

VL - 24

SP - 540

EP - 546

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 6

ER -